(R)-2-(N-(2-azidoethyl)-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide | 1449846-45-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-2-(N-(2-azidoethyl)-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide
• 英文别名: (2R)-2-[2-azidoethyl-(4-methoxyphenyl)sulfonylamino]-N-hydroxy-3-methylbutanamide
• CAS: 1449846-45-0
• 化学式: C₁₄H₂₁N₅O₅S
• 分子量: 371.417
• InChiKey: OPJBQWSZZMIIHX-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  5-fluoropent-1-yne 、 (R)-2-(N-(2-azidoethyl)-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide 在 copper(ll) sulfate pentahydrate 、 sodium ascorbate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 以38%的产率得到(R)-2-(N-(2-(4-(3-fluoropropyl)-1H-1,2,3-triazol-1-yl)ethyl)-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide
  参考文献：
  名称：

  Inverse 1,2,3-Triazole-1-yl-ethyl Substituted Hydroxamates as Highly Potent Matrix Metalloproteinase Inhibitors: (Radio)synthesis, in Vitro and First in Vivo Evaluation

  摘要：

  Noninvasive imaging and quantification of matrix metalloproteinase (MMP) activity in vivo are of great (pre)clinical interest. This can potentially be realized by using radiolabeled MMP inhibitors (MMPIs) as positron emission tomography (PET) imaging agents. Triazole-substituted MMPIs, discovered by our group, are highly potent inhibitors of MMP-2, -8, -9, and -13. The triazole ring and its position contribute significantly to the potency of the MMP inhibitor. To evaluate structure activity relationships (SARs) of the initially discovered triazole-substituted MMPIs, an additional CH2-group between the backbone of the molecule and the triazole core was inserted, and the triazole ring was "inversed" by switching the alkyne and azide groups. Similar to the original triazole-substituted hydroxamates, the inverse triazole MMPIs are excellent inhibitors with promising in vivo properties. Pharmacokinetic properties and metabolic stability of an F-18-labeled candidate in mice were investigated.

  DOI：

  10.1021/jm4006753
• 作为产物：
  描述：

  (R)-tert-butyl 2-(4-methoxyphenylsulfonamido)-3-methylbutanoate 在 N-甲基吗啉 、 盐酸 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 、 乙腈 、 N,N-dimethyl-d₆-formamide 为溶剂， 反应 68.5h， 生成 (R)-2-(N-(2-azidoethyl)-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide
  参考文献：
  名称：

  Inverse 1,2,3-Triazole-1-yl-ethyl Substituted Hydroxamates as Highly Potent Matrix Metalloproteinase Inhibitors: (Radio)synthesis, in Vitro and First in Vivo Evaluation

  摘要：

  Noninvasive imaging and quantification of matrix metalloproteinase (MMP) activity in vivo are of great (pre)clinical interest. This can potentially be realized by using radiolabeled MMP inhibitors (MMPIs) as positron emission tomography (PET) imaging agents. Triazole-substituted MMPIs, discovered by our group, are highly potent inhibitors of MMP-2, -8, -9, and -13. The triazole ring and its position contribute significantly to the potency of the MMP inhibitor. To evaluate structure activity relationships (SARs) of the initially discovered triazole-substituted MMPIs, an additional CH2-group between the backbone of the molecule and the triazole core was inserted, and the triazole ring was "inversed" by switching the alkyne and azide groups. Similar to the original triazole-substituted hydroxamates, the inverse triazole MMPIs are excellent inhibitors with promising in vivo properties. Pharmacokinetic properties and metabolic stability of an F-18-labeled candidate in mice were investigated.

  DOI：

  10.1021/jm4006753

文献信息

• [EN] COMPOUNDS WITH MATRIX-METALLOPROTEINASE INHIBITORY ACTIVITY<br/>[FR] COMPOSÉS AVEC ACTIVITÉ INHIBITRICE DE MÉTALLOPROTÉINASE DE MATRICE
  申请人：UNIV MUENSTER

  公开号：WO2013010573A1

  公开（公告）日：2013-01-24

  The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the inhibitors of matrix-metalloproteinases (MMPs) of the invention and of the diagnostic imaging agents of the invention.

  本发明涉及治疗和诊断试剂领域，更具体地涉及一种具有式（I）的化合物，该化合物是基质金属蛋白酶（MMPs）的抑制剂，并且在治疗与之相关的疾病如心血管疾病、炎症性疾病和恶性疾病方面有用。本发明的一个实施例是一种带有18-氟原子的式（I）化合物，具有适用于诊断成像的基质金属蛋白酶抑制活性。本发明还公开了一种包含本发明的基质金属蛋白酶（MMPs）抑制剂或相应标记化合物的制药组合物，适合于哺乳动物管理。此外，本发明还公开了在合成本发明的基质金属蛋白酶（MMPs）抑制剂和诊断成像剂中的中间体。